Today's Stock News: Latest Updates on Public Companies
588 news published.
Big earnings and guidance movers
UnitedHealth Group (UNH) posted first‑quarter 2026 results that investors will parse for Medicare trends and benefits‑management margins; see the official release.
Quest Diagnostics (DGX) beat prior guidance and raised revenue and EPS outlook for 2026, signaling durable diagnostics demand — read the details.
Equifax (EFX) delivered record Q1 revenue, coming in $37 million above the midpoint of guidance — a nod to pricing power in data services (more).
MSCI reported Q1 results investors watch for subscription resilience and index‑licensing trends that support recurring revenue (release).
AI, platforms and enterprise software moves
SoundHound AI (SOUN) agreed to acquire LivePerson, combining proprietary voice agentic AI with digital messaging to build an end‑to‑end conversational platform — a deal that tightens competition among AI‑first communications vendors.
Cognizant (CTSH) partnered with OpenAI to embed Codex capabilities into enterprise engineering workflows, reinforcing systems integrators as AI delivery leaders.
CGI (GIB) and OpenAI launched Codex for enterprises to accelerate developer productivity — another sign professional services firms are chasing AI implementation spend.
Snowflake (SNOW) expanded Snowflake Intelligence and Cortex Code to serve as the control plane for agentic deployments, tightening its role in governing data‑driven AI agents (announcement).
IBM introduced industry solutions for AI‑powered experience orchestration with Adobe, a partnership that could accelerate enterprise AI adoption across customer journeys (release).
Adobe (ADBE) and Comcast’s Xfinity announced a co‑innovation on deep brand intelligence for marketing campaigns, a move that highlights demand for AI‑driven customer analytics in media buys — see the announcement.
Defense, aerospace and program wins
Lockheed Martin (LMT) launched a GPS III satellite today, a reminder that space modernization continues to underpin predictable defense revenue streams (official note).
HII (HII) signed a strategic MOU with Applied Intuition to advance AI‑defined warship capabilities, reflecting industry bets on autonomy, simulation and software‑driven systems (MOU).
RTX reported Q1 2026 results; investors are focused on margin trends across Aero Engines and Defense Systems as integration continues (statement).
Financial, credit and capital moves to watch
Core Scientific (CORZ) proposed a $3.3 billion offering of senior secured notes — a large financing that will reshape the bitcoin‑miner’s capital structure and merits close monitoring (offering filing).
Churchill Downs (CHDN) struck a definitive agreement to acquire the Preakness intellectual property rights, a strategic consolidation that could unlock new media and event monetization plans (deal terms).
Invesco/Institutional Investment Trends (IVZ) highlights that institutional investors are rapidly expanding ETF usage, a structural flow story that can reshape demand for passive strategies and affect fund‑management revenue pools (report).
Healthcare, biotech and ASCO highlights (market‑moving items)
Moderna (MRNA) received European Commission marketing authorization for mCOMBRIAX, its mRNA combination vaccine against influenza and COVID‑19 — a regulatory win that expands commercial footprint in vaccines. Moderna also announced it will present data at ASCO 2026, which investors will watch for implications on platform versatility and vaccine R&D cadence (authorization note).
Pfizer (PFE) is showcasing oncology innovation and its next‑generation pipeline at ASCO 2026. Investors will look for late‑stage readouts and combo strategies that influence near‑term commercial forecasts and alliance activity.
Regeneron (REGN) reported that cemdisiran, dosed subcutaneously every 12 weeks, demonstrated rapid, deep and sustained disease control in a Phase 3 trial for generalized myasthenia gravis — a positive registrational readout that could reshape near‑term commercial opportunity in neurology (read more).
Cogent Biosciences (COGT) announced an oral presentation of positive Phase 3 PEAK trial results in GIST at ASCO 2026, a clinical milestone that can reset R&D expectations and partnering interest (announcement).
Incyte (INCY) highlighted new Phase 3 tafasitamab data to be discussed at ASCO 2026, data that investors will parse for durability and combination strategy implications (details).
Black Diamond Therapeutics (BDTX) announced an oral presentation of Phase 2 silevertinib data in frontline EGFRm NSCLC at ASCO 2026. Targeted lung cancer readouts like this can influence licensing interest and partnership timing.
Karyopharm (KPTI) had its Phase 3 SENTRY trial in myelofibrosis selected for a late‑breaking oral presentation at ASCO 2026 — a designation that typically signals potentially practice‑changing results and can trigger re‑rating if outcomes surprise to the upside (notice).
Immunome (IMNM) announced an oral presentation of Phase 3 RINGSIDE data at ASCO 2026; late‑stage registrational data releases like this can rapidly shift valuation assumptions for oncology biologics (details).
IDEAYA Biosciences (IDYA) announced a late‑breaking abstract oral presentation at ASCO 2026 for darovasertib plus crizotinib in 1L HLA*A2‑negative metastatic uveal melanoma — a focused registrational dataset that investors will assess for commercial niche potential (announcement).
Cellectar Biosciences (CLRB) had a subset of CLOVER WaM clinical trial data accepted for presentation at ASCO 2026, an outcome that can attract attention from partners and acquirers if the data suggest differentiated activity (release).
Selected oncology and ASCO presentation roundup
Additional ASCO items to note — companies with accepted oral/poster presentations that could move R&D narratives include Immatics (IMTX), Bicycle Therapeutics (BCYC), Zentalis Pharmaceuticals (ZNTL), Aprea Therapeutics (APRE), and NextCure (NXTC). Watch abstracts and poster timing for headline‑making datasets (Immatics, Bicycle, Zentalis).
- Also in focus today: Applied Materials (AMAT), RTX, and IBM as markets digest earnings, partnerships and financing moves.
Don't miss out on market-moving news. Bookmark this page and check back regularly for the most recent updates on stocks, sectors, and the overall market landscape. Stay informed, stay ahead, and make smarter investment choices with our comprehensive stock news coverage.
Stay ahead of the market with our list of today's most important stock news and financial updates. Whether you're a day trader, long-term investor, or market enthusiast, our news feed covers everything you need to know about publicly traded companies.
Our news feed is designed for investors who want to stay informed about the latest developments affecting their portfolio or watchlist. Whether you're researching potential investments, monitoring your current holdings, or simply staying up-to-date with market trends, our stock news page provides the information you need to make informed decisions.
What You'll Find on This Page:
- Breaking financial news and market-moving headlines
- FDA approvals and clinical trial results for biotech and pharma stocks
- Stock offerings, dividends, and other corporate actions
- Mergers, acquisitions, and strategic partnerships
- Business news affecting company performance and stock prices
- Easy-to-use tags for quick news categorization
- Stock tickers for instant company identification
- AI sentiment analysis to gauge market reaction
- Estimated impact scores to assess potential stock movement